Gain Therapeutics, Inc.
We are a development-stage biotechnology company developing novel therapeutics to treat rare genetic diseases and neurological disorders caused by protein misfolding, with an initial focus on lysosomal storage disorders (“LSDs”). We use our exclusively in-licensed proprietary platform, Site-Directed Enzyme Enhancement Therapy (“SEE-Tx”), to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules […]
March 1, 2021 Read More